Unlock instant, AI-driven research and patent intelligence for your innovation.

Biomarkers

a biomarker and sclerosis technology, applied in the field of multiple sclerosis diagnosis or monitoring, can solve the problems of axons not being able to effectively conduct signals, progressing to physical and cognitive disability, and going away completely

Inactive Publication Date: 2012-03-22
CAMBRIDGE ENTERPRISE LTD
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0021](c) comparing the amounts of the analyte biomarkers in the biological sample with the amounts present in a sample obtained from the individual on a pr

Problems solved by technology

When myelin is lost, the axons can no longer effectively conduct signals.
Almost any neurological symptom can appear with the disease, and often progresses to physical and cognitive disability.
Between attacks, symptoms may go away completely, but permanent neurological problems often occur, especially as the disease advances.
There is no known cure for multiple sclerosis.
Multiple sclerosis medications can have adverse effects or be poorly tolerated, and many patients pursue alternative treatments, despite the lack of supporting scientific study.
The prognosis is difficult to predict; it depends on the subtype of the disease, the individual patient's disease characteristics, the initial symptoms and the degree of disability the person experiences as time advances.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers
  • Biomarkers

Examples

Experimental program
Comparison scheme
Effect test

example 1

Study of Patients with Clinical Isolated Syndrome (CIS)

[0140]This study investigated levels of 247 molecular analytes in serum from 61 patients suffering from a clinical isolated syndrome suggestive of multiple sclerosis (CIS) and well matched controls (n=59). Demographic details can be found in Table 2:

TABLE 2Demographic details of patients and healthy volunteersHealthyControlsMS and CISNumber5961Sex (m / f)31 / 28Age30.2 ± 7.8Bmi23.2 ± 3.6

Applying T-tests, levels of 102 analytes were found to be significantly altered between the disease and the control group (Table 3):

TABLE 3Statistically significant analytes in patients with CISAnalyteP-valueQ-valueFold changeIL-157.17E−261.77E−230.598018Complement 31.89E−232.33E−211.580002TECK3.23E−222.66E−200.225676IL-179.85E−216.08E−192.027269Alpha 2 Macroglobulin8.15E−174.03E−152.389921IGF-11.25E−155.15E−144.816325IL-71.56E−155.51E−140.624483IL-102.76E−158.53E−140.707722Thrombopoietin6.71E−151.84E−130.604496BDNF (Brain Derived1.67E−144.12E−130.62...

example 2

Study of Patients with Definitive Diagnosis of Multiple Sclerosis

[0143]This study was performed in an analogous manner to that described in Example 1 wherein samples from 32 patients with a definite diagnosis of multiple sclerosis were analysed. When comparing the samples with control samples, the analytes listed in Table 4 were identified as being statistically significant (p<0.05). Statistical data is presented in Table 4 for the 6 analytes which were not considered significant in Example 1:

TABLE 4Statistically significant analytes in patients with MultipleSclerosisAnalyteP-valueQ-valueIL-15Complement 3TECKIL-17Alpha 2 MacroglobulinIGF-1IL-7IL-10ThrombopoietinBDNF (Brain Derived NeurotrophicFactor)IL-13HGF (Hepatocyte growth factor)Factor VIIEndothelin 1FibrinogenEGFAngiotensinogenApolipoprotein CIIITNF alphaRANTESFas LigandHistone H3 AntibodyCD40 LigandResistinBetacellulinMIP-1 betaCD40Stem Cell FactorACE (Angiotensin ConvertingEnzyme)HCC-4EN-RAGEIL-12 p70Histone H1 AntibodyEpire...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a method of diagnosing or monitoring multiple sclerosis.

Description

FIELD OF THE INVENTION[0001]The invention relates to a method of diagnosing or monitoring multiple sclerosis.BACKGROUND OF THE INVENTION[0002]Multiple sclerosis, also known as disseminated sclerosis or encephalomyelitis disseminata) is an autoimmune condition in which the immune system attacks the central nervous system, leading to demyelination. Disease onset usually occurs in young adults, and it is more common in females. It has a prevalence that ranges between 2 and 150 per 100,000.[0003]Multiple sclerosis affects the ability of nerve cells in the brain and spinal cord to communicate with each other. Nerve cells communicate by sending electrical signals, known as action potentials, down axons, which are wrapped in myelin. In multiple sclerosis, the body's own immune system attacks and damages the myelin. When myelin is lost, the axons can no longer effectively conduct signals. The name multiple sclerosis refers to scars (scleroses—better known as plaques or lesions) in the white...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C40B30/04C12Q1/48G01N33/68C12Q1/42G01N30/02C12Q1/37G01N33/573H01J49/26H01J49/40G01N33/566C12Q1/28
CPCG01N33/564G01N2800/60G01N2800/52G01N2800/285
Inventor BAHN, SABINESCHWARZ, EMANUEL
Owner CAMBRIDGE ENTERPRISE LTD